2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.12 Aggarwal

PP01.12 Aggarwal - Poster

Pdf Summary

A phase II clinical trial of selinexor was conducted in patients with advanced thymoma and thymic carcinoma, which are rare thymic epithelial tumors. The study aimed to assess the safety and efficacy of selinexor, an oral inhibitor of nuclear export, in patients with progressive disease post platinum-based chemotherapy treatment. The trials, conducted in the U.S. and Europe, included patients with advanced, inoperable TETs. Patients received selinexor twice weekly, and due to poor tolerability, the starting dose was reduced. Results indicated modest anticancer activity of selinexor with low overall response rates but some patients showed prolonged stable disease. Common treatment-related adverse events included nausea, vomiting, anemia, and fatigue. Despite these findings, the trials did not progress to the planned second phase due to low response rates and slow enrollment. Overall, selinexor demonstrated some efficacy in pretreated advanced TET patients, warranting further research to improve outcomes in these rare tumors.

Keywords

selinexor

phase II clinical trial

thymoma

thymic carcinoma

nuclear export inhibitor

platinum-based chemotherapy

TETs

anticancer activity

adverse events

clinical trial results